Organon Wins Patent Dispute
A District Court in Germany has ruled that Organon Teknika, a subsidiary of the Dutch chemical and pharmaceutical group Akzo Nobel, does not directly or indirectly infringe nucleic acid amplification patents owned by Swiss company Hoffmann-La Roche.
Organon manufactures and sells diagnostic tests for HIV, which are based on its patented NASBA nucleic acid amplification technology. Roche alleges that the NASBA technology infringes its patents on the PCR amplification technology.
The Court found that the NASBA technology is fundamentally different from the procedure protected by the Hoffmann-La Roche patents. Organon says it is confident that the current litigation in France, the USA and the UK, as well as any appeal procedures, will also be decided in the company's favor.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze